^
    The NeoLAB Solid Tumor Liquid Biopsy is a next-gen sequencing assay designed to detect mutations in cell-free circulating tumor DNA of patients with solid tumors (pan-cancer). Analytic validation demonstrated accuracy of 98.0%, sensitivity of 95.1%, and specificity of 98.8%. The NeoLAB® Solid Tumor Liquid Biopsy includes targets significant to a wide variety of solid tumors including colorectal, pancreas, prostate, melanoma, head & neck, bladder, thyroid, kidney, ovarian, liver, thyroid, breast, and lung. Tissue testing is recommended over plasma testing when possible.
    Cancer:
    Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Thyroid Gland Carcinoma
    Gene:
    AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), AR (Androgen receptor), ARAF (A-Raf Proto-Oncogene), BRAF (B-raf proto-oncogene)
    See More ...
    Method:
    Next-Generation Sequencing (NGS)